A prospective carriage and serological study was conducted in Burkina Faso during the 2003 meningitis season, which was characterized by hyperendemic Neisseria meningitidis serogroup W135 (NmW135) and serogroup A (NmA) disease. Participants were evaluated five times at monthly intervals. In the presence of moderate NmW135 carriage, we found a low prevalence of putatively protective levels of specific immunoglobulin G (IgG) and serum bactericidal antibody (SBA) against NmW135. Specific IgG concentrations and SBA titers against NmA were relatively high in this recently vaccinated population, while no NmA carriage was detected. NmW135 carriage infrequently induced protective immunity against reference or homologous strains, while natural immunity against NmW135 was frequently lost. A vaccine that is effective against W135 will be beneficial for sub-Saharan Africa.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2007.04.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety, Tolerability, and Immunogenicity of the Invaplex Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.
Vaccines (Basel)
January 2025
Leiden University Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over a 20-year period. A challenge to effective Shigella vaccine development has been the low immunogenicity and protective efficacy of candidate Shigella vaccines in infants and young children.
View Article and Find Full Text PDFAssessing the Acceptability and Feasibility of Five Cycles of Seasonal Malaria Chemoprevention in Côte d'Ivoire.
Trop Med Infect Dis
December 2024
National Institute of Public Health, Abidjan BP V 47, Côte d'Ivoire.
Seasonal malaria chemoprevention (SMC) is a strategy recommended by the World Health Organization for children aged 3-59 months in the Sahel and sub-Sahel regions where malaria transmission is seasonal. In Côte d'Ivoire, malaria remains a high priority and accounts for the majority of consultations and deaths in children under five. The recent revision of the criteria for the introduction of seasonal malaria chemoprevention has made the north of Côte d'Ivoire, where malaria transmission is seasonal, eligible for the SMC.
View Article and Find Full Text PDFFecal carriage of carbapenemase and AmpC-β-lactamase producers among extended spectrum β-Lactamase-producing E. coli and Klebsiella spp. isolates in patients attending hospitals.
BMC Infect Dis
January 2025
Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Ouagdougou, 11 BP218, Burkina Faso.
Background: Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE), particularly Escherichia coli and Klebsiella pneumoniae, have been consistently associated with treatment failure, high mortality and morbidity. The emergence of carbapenem resistance among ESBL-PE strains exacerbates the antimicrobial resistance. However, data are very limited in developing countries as Burkina Faso.
View Article and Find Full Text PDFVaccine-derived poliovirus type 3 emergence in Guinea, 2024.
Lancet Infect Dis
January 2025
WHO, Conakry, Guinea.
Access to plasma viral load in people living with HIV under treatment in Ouagadougou and Bobo Dioulasso, Burkina Faso.
IJID Reg
March 2025
Department of Public Health, RTU/HS, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Objectives: Less than 25% of people living with HIV (PLWHIV) achieved plasma viral load (PVL) in 2020 in Burkina Faso. This study aimed to identify factors associated with access to PVL in Ouagadougou and Bobo-Dioulasso.
Methods: A cross-sectional analytical study was conducted among PLWHIV in Burkina Faso between April 15 and August 8, 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!